NSCLC, early stage Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer

Authors:
  • PFP.M. Forde
    P.M. Forde
  • KSK.N. Smith
    K.N. Smith
  • JCJ.E. Chaft
    J.E. Chaft
  • MHM. Hellmann
    M. Hellmann
  • TMT. Merghoub
    T. Merghoub
  • JWJ.D. Wolchok
    J.D. Wolchok
  • SYS.C. Yang
    S.C. Yang
  • RBR.J. Battafarano
    R.J. Battafarano
  • EGE. Gabrielson
    E. Gabrielson
  • CGC.S. Georgiades
    C.S. Georgiades
  • FVF. Verde
    F. Verde
  • GRG.L. Rosner
    G.L. Rosner

Abstract
Background: Nivolumab is a PD-1 inhibitor that has demonstrated durable responses and improved survival in patients (pts) with previously treated, metastatic non-small-cell lung cancer (NSCLC). This is the first report of neoadjuvant PD-1 blockade in pts with early stage NSCLC.
Funding Information
  • Bristol-Myers Squibb